Ropes & Gray advised Johnson & Johnson in an agreement to acquire Firefly Bio and its novel degrader-antibody conjugate (DAC) platform targeted toward KRAS-driven solid tumors for $1 billion in cash to expand its oncology pipeline. The transaction was announced on June 8 and completed on July 29.
The Ropes & Gray team was led by mergers & acquisitions partner Matt Byron and included IP transactions partner David McIntosh, tax partner Amanda Holt, employment, executive compensation & benefits principal Abby Meyer and senior benefits consultant Ben Asch.
Stay Up To Date with Ropes & Gray
Ropes & Gray attorneys provide timely analysis on legal developments, court decisions and changes in legislation and regulations.
Stay in the loop with all things Ropes & Gray, and find out more about our people, culture, initiatives and everything that’s happening.
We regularly notify our clients and contacts of significant legal developments, news, webinars and teleconferences that affect their industries.